Evidence map›Paper›PMID 32352101›Full record

ReviewBiomaterials science2020

Protein cages and virus-like particles: from fundamental insight to biomimetic therapeutics.

Nicole F Steinmetz, Sierin Lim, Frank Sainsbury

Abstract readReview
In one paragraph

Review in Biomaterials science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed.

  1. Review
  2. Harnessing Nanocarriers to Advance Vaccine Development.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026
    Review
  3. Pleomorphism in Wild-Type and Engineered PP7 Virus-Like Particles.Small (Weinheim an der Bergstrasse, Germany) · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Protein Cage Directed Assembly of Binary Nanoparticle Superlattices.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. An interaction network approach predicts protein cage architectures in bionanotechnology.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  14. Bioengineered nanotechnology for nucleic acid delivery.Journal of controlled release : official journal of the Controlled Release Society · 2023
    Review
  15. Review
  16. Computational design of non-porous, pH-responsive antibody nanoparticles.bioRxiv : the preprint server for biology · 2023
    Article
  17. Article
  18. Article
  19. Review
  20. mRNA nanomedicine: Design and recent applications.Exploration (Beijing, China) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Nicole F SteinmetzDepartment of NanoEngineering, University of California, San Diego, CA 92093, USA and Department of Bioengineering, University of California, San Diego, CA 92093, USA and Department of Radiology, University of California, San Diego, CA 92093, USA and Moores Cancer Center, University of California, San Diego, CA 92093, USA and Center for Nano-ImmunoEngineering, University of California, San Diego, CA 92093, USA.ORCID http://orcid.org/0000-0002-0130-0481
Sierin LimSchool of Chemical and Biomedical Engineering, Nanyang Technological University, Singapore 637457, Singapore and NTU-Northwestern Institute for Nanomedicine, Nanyang Technological University, Singapore 637457, Singapore.ORCID http://orcid.org/0000-0001-7455-6771
Frank SainsburyCentre for Cell Factories and Biopolymers, Griffith Institute for Drug Discovery, Griffith University, Nathan, QLD 4111, Australia. f.sainsbury@griffith.edu.au and Synthetic Biology Future Science Platform, Commonwealth Scientific and Industrial Research Organisation (CSIRO), Brisbane, QLD 4001, Australia.ORCID http://orcid.org/0000-0001-8152-3820

Funding

Dual-pronged nano-drug delivery using plant virus-like particles.R01CA224605 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Nicole Franziska Steinmetz · 2017 to 2026
$4.0M
Overcoming the immune-suppressive tumor microenvironment through in situ vaccination nanotechnology.U01CA218292 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIERING, STEVEN, STEINMETZ, NICOLE FRANZISKA · 2017 to 2021
$3.0M
A theranostic approach for risk stratification and intervention of deep vein thrombosis.R01HL137674 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI STEINMETZ, NICOLE FRANZISKA · 2017 to 2020
$2.3M
Diagnosis and longitudinal monitoring of metastatic prostate cancer through molecular MR imaging.R01CA202814 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI STEINMETZ, NICOLE FRANZISKA · 2016 to 2020
$2.0M
Protein/Polymer Devices for Slow-Release of Immunotherapies to Treat Ovarian CancerR21EB024874 · NIBIB · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI POKORSKI, JONATHAN KYLE, STEINMETZ, NICOLE FRANZISKA · 2017 to 2018
$431k
NCI NIH HHS R01 CA202814NCI NIH HHS R01 CA224605NCI NIH HHS U01 CA218292NHLBI NIH HHS R01 HL137674NIBIB NIH HHS R21 EB024874
6 · The paper itself

Abstract

Protein cages (viral and non-viral) found in nature have evolved for a variety of purposes and are found in all kingdoms of life. The main functions of these nanoscale compartments are the protection and delivery of nucleic acids e.g. virus capsids, or the enrichment and sequestration of metabolons e.g. bacterial microcompartments. This review focuses on recent developments of protein cages for use in immunotherapy and therapeutic delivery. In doing so, we highlight the unique ways in which protein cages have informed on fundamental principles governing bio-nano interactions. With the enormous existing design space among naturally occurring protein cages, there is still much to learn from studying them as biomimetic particles.

Indexed as

BiomimeticsImmunotherapyBiocompatible MaterialsHumansModels, MolecularNanoparticlesProteinsVirusesBiocompatible MaterialsProteins

Identifiers

PMID32352101
PMCPMC8085892

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.